The Promise and Challenge of Induced Pluripotent Stem Cells (iPSCs): 2nd Edition

Dear Colleagues,

Since the first generation of induced pluripotent stem cells (iPSCs) in 2006, the development of iPSC technology has ushered in a revolutionary new era for studying diseases and developing therapies. Human iPSCs have unmatchable advantages, including pluripotency, potentially limitless expandability, easy accessibility, avoidance of ethical concerns associated with embryonic stem cells or human tissues, and the potential to develop patient-specific models for personalized medicine. These traits make iPSCs an ideal cell source for disease modeling, drug discovery, and regenerative medicine. One quickly evolving field of iPSC technology is the development of human-based in vitro disease models by utilizing patient-iPSCs or those generated by CRISPR/Cas9 gene editing. Through the integration of multidisciplinary technologies, these models are finding increasing applications in pathogenesis study and drug efficacy and toxicity testing. Another is for regenerative medicine, such as autologous or allogenic cell therapy, although they are still challenged by the high standard requirements for quality control. In summary, with the assistance of other technologies, iPSC technology holds great promise for tackling human diseases.

In this Special Issue, studies in all the fields of iPSC technology are invited, from stem cell generation and differentiation to disease modeling and stem cell therapy; progress or challenges encountered; and in vitro or in vivo. Studies reporting breakthrough discoveries in the scientific understanding of iPSC or technological developments will be particularly encouraged. Both research articles and reviews are welcome.

Dr. Xiufang Guo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• iPSC
• cell differentiation
• disease model
• disease-in-a-dish
• body-on-a-chip
• CRISPR/Cas9
• gene edition
• stem cell therapy
• cell transplantation
• translational

• The Promise and Challenge of Induced Pluripotent Stem Cells (iPSCs) in Biomedicines (7 articles)